fig1

Figure 1. Identification of potential biomarkers predicting bevacizumab efficacy in CRC. (A) Scatter plot of upregulated differential expression genes (DEGs) in pre-treated colorectal cancer compared to mucosa in bevacizumab responders in dataset GSE60331. The DEGs were ranked in descending order by logFC along the X-axis. The color depth represents -log(adjusted P-value); (B) Scatter plot of upregulated differential expression genes (DEGs) in pre-treated colorectal cancer compared to mucosa in bevacizumab non-responders in dataset GSE60331. The DEGs were ranked in descending order by logFC along the X-axis. The color depth represents -log(adjusted P-value); (C) Venn diagram of DEGs in responders and non-responders; (D) Scatter plot of -log(P-value) from two survival analyses. The X-axis represents the -log(P-value) of the hazard ratio (HR) in the Cox proportional hazard model, and the Y-axis represents the -log(P-value) of the Log-rank test. The genes were marked with different colors and were ranked by risk to patient survival in descending order on the right side of the plot based on a combination of -log(P-value) values on the X-axis and Y-axis; (E and F) The expression of MAGEA3 (E) and ANGPT2 (F) in colorectal cancer and normal colon tissue in TCGA database. DEGs: differential expression genes; FC: fold change; HR: hazard ratio.